Comparing Treatment Responses of Lebrikizumab, Dupilimab and Tralokinumab in Treating AD

This study explores the importance of treatment durability in real-world settings when managing chronic diseases like atopic dermatitis (AD), where symptoms can fluctuate over time, patients can pause treatments or not fully adhere to their prescribed regimens.

Recent phase 3 monotherapy trials suggest that the effects of treatment interruptions may differ for dupilumab, tralokinumab, and lebrikizumab. Enter the "durability index" (DI): a new measure that evaluates a drug’s ability to maintain efficacy both on and off therapy at the population level.

This indirect comparative analysis reveals that biologics vary in their ability to maintain population-level efficacy at different treatment continuance rates. Lebrikizumab showed significantly higher treatment responses compared to dupilumab and tralokinumab across most continuance rates, particularly at lower rates. This suggests that lebrikizumab may provide better response maintenance in real-life scenarios where treatment interruptions and suboptimal continuance rates are common.

For a link to the original poster, click here.

Elevate-Derm Alliance Editorial Committee